Cargando…

Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Since their description and identification in leukemias and solid tumors, cancer stem cells (CSC) have been the subject of intensive research in translational oncology. Indeed, recent advances have led to the identification of CSC markers, CSC targets, and the preclinical and clinical evaluation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulenburg, Axel, Blatt, Katharina, Cerny-Reiterer, Sabine, Sadovnik, Irina, Herrmann, Harald, Marian, Brigitte, Grunt, Thomas W, Zielinski, Christoph C, Valent, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345016/
https://www.ncbi.nlm.nih.gov/pubmed/25886184
http://dx.doi.org/10.1186/s13045-015-0113-9
_version_ 1782359513280544768
author Schulenburg, Axel
Blatt, Katharina
Cerny-Reiterer, Sabine
Sadovnik, Irina
Herrmann, Harald
Marian, Brigitte
Grunt, Thomas W
Zielinski, Christoph C
Valent, Peter
author_facet Schulenburg, Axel
Blatt, Katharina
Cerny-Reiterer, Sabine
Sadovnik, Irina
Herrmann, Harald
Marian, Brigitte
Grunt, Thomas W
Zielinski, Christoph C
Valent, Peter
author_sort Schulenburg, Axel
collection PubMed
description Since their description and identification in leukemias and solid tumors, cancer stem cells (CSC) have been the subject of intensive research in translational oncology. Indeed, recent advances have led to the identification of CSC markers, CSC targets, and the preclinical and clinical evaluation of the CSC-eradicating (curative) potential of various drugs. However, although diverse CSC markers and targets have been identified, several questions remain, such as the origin and evolution of CSC, mechanisms underlying resistance of CSC against various targeted drugs, and the biochemical basis and function of stroma cell-CSC interactions in the so-called ‘stem cell niche.’ Additional aspects that have to be taken into account when considering CSC elimination as primary treatment-goal are the genomic plasticity and extensive subclone formation of CSC. Notably, various cell fractions with different combinations of molecular aberrations and varying proliferative potential may display CSC function in a given neoplasm, and the related molecular complexity of the genome in CSC subsets is considered to contribute essentially to disease evolution and acquired drug resistance. In the current article, we discuss new developments in the field of CSC research and whether these new concepts can be exploited in clinical practice in the future.
format Online
Article
Text
id pubmed-4345016
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43450162015-03-02 Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? Schulenburg, Axel Blatt, Katharina Cerny-Reiterer, Sabine Sadovnik, Irina Herrmann, Harald Marian, Brigitte Grunt, Thomas W Zielinski, Christoph C Valent, Peter J Hematol Oncol Review Since their description and identification in leukemias and solid tumors, cancer stem cells (CSC) have been the subject of intensive research in translational oncology. Indeed, recent advances have led to the identification of CSC markers, CSC targets, and the preclinical and clinical evaluation of the CSC-eradicating (curative) potential of various drugs. However, although diverse CSC markers and targets have been identified, several questions remain, such as the origin and evolution of CSC, mechanisms underlying resistance of CSC against various targeted drugs, and the biochemical basis and function of stroma cell-CSC interactions in the so-called ‘stem cell niche.’ Additional aspects that have to be taken into account when considering CSC elimination as primary treatment-goal are the genomic plasticity and extensive subclone formation of CSC. Notably, various cell fractions with different combinations of molecular aberrations and varying proliferative potential may display CSC function in a given neoplasm, and the related molecular complexity of the genome in CSC subsets is considered to contribute essentially to disease evolution and acquired drug resistance. In the current article, we discuss new developments in the field of CSC research and whether these new concepts can be exploited in clinical practice in the future. BioMed Central 2015-02-25 /pmc/articles/PMC4345016/ /pubmed/25886184 http://dx.doi.org/10.1186/s13045-015-0113-9 Text en © Schulenburg et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Schulenburg, Axel
Blatt, Katharina
Cerny-Reiterer, Sabine
Sadovnik, Irina
Herrmann, Harald
Marian, Brigitte
Grunt, Thomas W
Zielinski, Christoph C
Valent, Peter
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
title Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
title_full Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
title_fullStr Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
title_full_unstemmed Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
title_short Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
title_sort cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345016/
https://www.ncbi.nlm.nih.gov/pubmed/25886184
http://dx.doi.org/10.1186/s13045-015-0113-9
work_keys_str_mv AT schulenburgaxel cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication
AT blattkatharina cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication
AT cernyreiterersabine cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication
AT sadovnikirina cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication
AT herrmannharald cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication
AT marianbrigitte cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication
AT gruntthomasw cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication
AT zielinskichristophc cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication
AT valentpeter cancerstemcellsinbasicscienceandintranslationaloncologycanwetranslateintoclinicalapplication